Harnessing the microbiome to transform lives

Harnessing the
microbiome
to transform lives

Corporate profile

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs.

With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for recurrent C. difficile infection (CDI). In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch is also developing CP101 for chronic hepatitis B, and FIN-211 for autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for ulcerative colitis and Crohn’s disease, respectively.

Press releases

Finch Therapeutics to Participate in the Jefferies Microbiome-Based Therapeutics Summit
Apr 15, 2021
Finch Therapeutics Announces Pricing of Upsized Initial Public Offering
Mar 18, 2021
Finch Therapeutics Presents Data from its Positive PRISM3 Trial of CP101 in Recurrent C. difficile Infection at Two Leading Medical Conferences
Oct 28, 2020

Events & presentations

Jefferies Microbiome-Based Therapeutics Summit

Apr 22, 2021
Latest presentation
Please check back for our latest corporate presentation.